Qulipta (atogepant) belongs to the oral generation of CGRP therapies, which followed the injectable antibodies that first moved migraine prevention beyond repurposed drugs.
As a CGRP receptor antagonist, it blocks the peptide signaling involved in triggering attacks, without the vasoconstriction that limits older triptans. The once-daily tablet is approved for the preventive treatment of migraine in adults, initially episodic and later extended to chronic migraine.
Qulipta faces no generic competition but competes directly with rimegepant and the injectable CGRP antibodies. Oral convenience, once-daily dosing, and payer step-therapy requirements are the main variables shaping its position in migraine prevention.
